Ulixertinib

Drug Profile

Ulixertinib

Alternative Names: BVD-523; BVD-ERK; BVD-ERK/HM; BVD-ERK/ST; VRT-0752271; VRT-752271; VX-271

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer BioMed Valley Discoveries; Dana-Farber Cancer Institute
  • Class Aminopyridines; Antineoplastics; Pyrroles; Small molecules
  • Mechanism of Action Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Uveal melanoma
  • Phase I/II Acute myeloid leukaemia; Cancer; Myelodysplastic syndromes
  • Phase I Pancreatic cancer; Solid tumours

Most Recent Events

  • 05 Mar 2018 Phase-I clinical trials in Pancreatic cancer (Combination therapy, In the elderly, Late-stage disease, Second-line therapy or greater, In adults, Metastatic disease) in USA (PO) (NCT03454035)
  • 05 Mar 2018 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, In the elderly, In adults, Combination therapy) in USA (PO) (NCT03454035)
  • 01 Mar 2018 Phase-II clinical trials in Uveal melanoma (Metastatic disease, Late-stage disease) in USA (PO) (NCT03417739)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top